People · Operator
Named in public records as an officer, director or promoter · active 2012–2014 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xeris Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $86.5M | $1.1B | 2012 |
Shane Brisbin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shane Brisbin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Timothy Sullivan | 1 | 16 |
| Jonathan Rigby | 1 | 4 |
| Douglas Baum | 1 | 3 |
| Navneet Puri | 1 | 3 |
| Phillip Johnson | 1 | 2 |
| John Shannon | 1 | 2 |
| John Kinzell | 1 | 1 |
| Doug Baum | 1 | 1 |
| John Kinzel | 1 | 1 |
| Robert Faulker | 1 | 1 |
| Mark Saliman | 1 | 1 |
| Cary McNair | 1 | 1 |
| Yash Sabharwal | 1 | 1 |
| Paul Edick | 1 | 1 |
| Poul Strange | 1 | 1 |
| Brad Huckabee | 1 | 1 |
| Steven Prestrelski | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.